Nymox Pharmaceutical Corp
NYMX
NYMX was delisted on the 6th of July, 2023.
37 hedge funds and large institutions have $444K invested in Nymox Pharmaceutical Corp in 2022 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 5 closing their positions.
700% more call options, than puts
Call options by funds: $16K | Put options by funds: $2K
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
9% more funds holding
Funds holding: 34 → 37 (+3)
0% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 8
10% less capital invested
Capital invested by funds: $495K → $444K (-$50.9K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$30.5K |
| 2 |
Renaissance Technologies
New York
|
+$30K |
| 3 |
CAN
Cetera Advisor Networks
El Segundo,
California
|
+$18.1K |
| 4 |
Jane Street
New York
|
+$9.1K |
| 5 |
VF
Virtu Financial
New York
|
+$7.11K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LSA
Leonteq Securities AG
Zurich,
Switzerland
|
-$27.4K |
| 2 |
Millennium Management
New York
|
-$16K |
| 3 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
-$14.6K |
| 4 |
GG
Gofen & Glossberg
Chicago,
Illinois
|
-$9.05K |
| 5 |
WCWM
Willow Creek Wealth Management
Sebastopol,
California
|
-$8K |
NYMX Hedge Fund Activity: Q4 2022 in Review
37 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Nymox Pharmaceutical Corp (NYMX) for Q4 2022, worth a combined $444K — down 10% from $495K a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new NYMX positions and 5 closed out — a net gain of 3 holders — while 8 added to existing stakes and 8 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $30.5K. The largest seller was Leonteq Securities AG, exiting entirely with an estimated $27.4K sold.
- 37 institutional investors held Nymox Pharmaceutical Corp (NYMX) as of Q4 2022, up from 34 in Q3 2022.
- Funds reported $444K of Nymox Pharmaceutical Corp stock for Q4 2022, down 10% quarter-over-quarter.
- 8 funds opened new Nymox Pharmaceutical Corp positions in Q4 2022 and 5 closed out, a net change of +3 holders.
- The largest Nymox Pharmaceutical Corp buyer in Q4 2022 was Citadel Advisors, an estimated $30.5K added.
- The largest Nymox Pharmaceutical Corp seller in Q4 2022 was Leonteq Securities AG, an estimated $27.4K sold.
Based on aggregated 13F filings for Q4 2022.